glp-1 weight loss study Study: US obesity rates are dropping as use increases Research, including new findings published

10.1007/s00125-016-3874-y 40 FlintA.KapitzaC.HindsbergerC.ZdravkovicM

Glucagon-like peptide-1 receptor (GLP-1R) Mahony L, Saunders P, Whitaker L et al

2025;24:e16716

Not every applicant will qualify - and that reflects appropriate clinical gatekeeping, not a platform limitation

Previously, GLP-1 medications which mimic the naturally occurring hormone glucagon-like peptide-1, which regulates blood sugar, digestion, and hunger had been approved only to treat obesity in the form of weekly, home-administered injections

As we step into a new, more accessible era of anti-obesity care, contributing to a sharper demand for GLP-1s and similar medications, its important that patients, providers and employers understand the key differences between formulations and how they impact health outcomes